The effectiveness of a two-component renin-angiotensin aldosterone system blockade after renal transplantation in patients with chronic terminal renal failure

Cover Page

Cite item

Full Text

Abstract

Conducted a study to determine the effectiveness of blood pressure (BP) control in patients after renal transplantation using a two renin-angiotensin aldosterone system (RAAS) blockade. Within 6 months after kidney transplantation is observed syndrome uncontrolled blood pressure (BP) in 51.6% patients; 13 transplant patients (69.2% men and 30.8% women; mean age 34.7±11.8 years) had chronic glomerulonephritis (100% of cases) as the main cause of end-stage chronic kidney disease. Patients received a dose of aliskiren 150-300 mg in combination with a sartans and calcium antagonist after signing informed consent. Within 2 months of treatment there was a significant deterioration in graft function in achieving optimal BP<130/80 mm Hg. The study showed a significant decrease glomerular filtration rate, uptrend resistance index arc and central vessels of the transplanted kidney, increasing proteinuria. The 2-3 therapy aliskiren and angiotensin receptor blockers was safe in terms of effect on the mineral, carbohydrate, protein exchanges.

About the authors

A. A Ostanina

City Hospital №1

зав. терапевтическим отд-нием МБУЗ ГБ №1 663321, Russian Federation, Norilsk, p/о Oganer

I. V Fomin

Nizhny Novgorod State Medical Academy of the Ministry of Health of the Russian Federation

Email: fomin-i@yandex.ru
зав. каф. внутренних болезней ГБОУ ВПО НижГМА 603005, Russian Federation, Nizhny Novgorod, pl. Minina I Pozharskogo, d. 10/1

D. S Polyakov

Nizhny Novgorod State Medical Academy of the Ministry of Health of the Russian Federation

ассистент каф. внутренних болезней ГБОУ ВПО НижГМА 603005, Russian Federation, Nizhny Novgorod, pl. Minina I Pozharskogo, d. 10/1

K. S Lipatov

Volga District Medical Centre under Federal Medical and Biological Agency of Russia

гл. нефролог ФБУЗ ПОМЦ 603001, Russian Federation, Nizhny Novgorod, Nizhnevolzhskaia nab., d. 2

G. A Shcherbakova

Volga District Medical Centre under Federal Medical and Biological Agency of Russia

зав. терапевтическим отд-нием Поликлиники №4 ФБУЗ ПОМЦ 603001, Russian Federation, Nizhny Novgorod, Nizhnevolzhskaia nab., d. 2

References

  1. Clase C.M, Garg A.X, Kiberd B.A. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; 13 (5): 1338-49.
  2. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2009 гг. (Отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ. 2011; 13 (3).
  3. Campistol J.M, Romero R, Paul J, Gutieґrrez-Dalmaul А. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 (Suppl. 3): 62-6.
  4. Kasiske B.L, Cangro C.B, Hariharan S et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 (Suppl. 2): 3-95.
  5. Curtis J.J. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep 2002; 4: 377-80.
  6. Mangus R.S, Haag B.W. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant 2004; 4 (11): 1889-96.
  7. Pampaloni F, Sanchez L.J, Bencini L, Taddei G. Simultaneous aortoiliac reconstruction and renal transplantation: is it safe? Chir Ital 2002; 54(1): 115-20.
  8. Cornell L.D, Smith R.N, Colvin R.B. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3: 189-220.
  9. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection: acute and chronic studies. Contrib Nephrol 2008; 159: 122-34.
  10. Webster A.C, Woodroffe R.C, Taylor R.S et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta - analysis and meta - regression of randomised trial data. BMJ 2005; 331 (7520): 810.
  11. Webster A.C, Lee V.W, Chapman J.R, Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta - analysis of randomized trials. Transplantation 2006; 81 (9): 1234-48.
  12. Lassila M. Interaction of cyclosporine A and the reninangiotensin system; new perspectives. Curr Drug Metab 2002; 3: 61-71.
  13. Segura J, Garcia-Donair J, Praga M et al. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol 2006; 17 (Suppl. 2.): 136-40.
  14. Foley R, Murray A, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-95.
  15. Hausberg M, Kosch M, Hohage H et al. Antihypertensive treatment in renal transplant patients - is there a role for ACE inhibitors? Ann Transplant 2001; 6: 31-7.
  16. Baroletti S.A, Gabardi S, Magee C.C, Milford E.L. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003; 23: 788-801.
  17. Noris M, Mister M, Pezzotta A et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64: 2253-61.
  18. Cross N.B, Webster A.C, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta - analysis of randomized controlled trials. Transplantation 2009; 88: 7-18.
  19. Parving H.H, Persson F, Lewis J.B et al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med 2008; 358: 2433-46.
  20. Persson F, Lewis J.B, Lewis E.J et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol 2011; 6 (5): 1025-31.
  21. Gansevoort R.T, Sluiter W.J, Hemmelder M.H et al. Antiproteinuric effect of blood - pressure - lowering agents: a meta - analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963-74.
  22. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259-305.
  23. Del Castillo D, Campistol J.M, Guirado L et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998; 68: S135-S139.
  24. Фомин И.В., Останина А.А., Поляков Д.С., Липатов К.С. Существует ли оптимальный уровень артериального давления у пациентов с терминальной хронической почечной недостаточностью до и после трансплантации почки? Совр. технологии в медицине. 2014; 6 (2): 53-60.
  25. Paoletti E, Gherzi M, Amidone M et al. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009; 87: 1864-9.
  26. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217-22.
  27. Мухин Н.А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Терапевт. арх. 2004; 9: 5-10.
  28. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С. Мочевая кислота - ключевой компонент кардиренометаболического континуума. Кардиоваск. терапия и профилактика. 2008; 4: 95-100.
  29. Parving H.H, Brenner B.M, Mc Murray J.J.V et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-13.
  30. Parving H.H, Brenner B.M, Mc Murray J.J et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13 (3): 387-93.
  31. Mann J.F.E, Schmieder R.E, Mc Queen M et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double - blind controlled trial. Lancet 2008; 372: 547-53.
  32. Inigo P, Campistol J.M, Lario S et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta (1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822-7.

Copyright (c) 2015 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies